Prothena carefully explains why it's killing a psoriasis drug after PhIb
Prothena is cutting its losses on one of its key drug development programs after concluding their therapy failed to pass muster in a Phase Ib …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
